Seres Historical Income Statement
| MCRB Stock | USD 0.58 0.05 7.94% |
Historical analysis of Seres Therapeutics income statement accounts such as Other Operating Expenses of 125.5 M can show how well Seres Therapeutics performed in making a profits. Evaluating Seres Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Seres Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Seres Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Seres Therapeutics is a good buy for the upcoming year.
Seres |
About Seres Income Statement Analysis
Seres Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Seres Therapeutics shareholders. The income statement also shows Seres investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Seres Therapeutics Income Statement Chart
Seres Therapeutics Income Statement is one of the three primary financial statements used for reporting Seres's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Seres Therapeutics revenue and expense. Seres Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Seres Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 13.8 M, whereas Other Operating Expenses is forecasted to decline to about 125.5 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Seres Therapeutics. It is also known as Seres Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Seres Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.At present, Seres Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 13.8 M, whereas Other Operating Expenses is forecasted to decline to about 125.5 M.
| 2023 | 2024 (projected) | Non Recurring | 1.3M | 1.2M | Reconciled Depreciation | 6.2M | 5.5M |
Seres Therapeutics income statement Correlations
Click cells to compare fundamentals
Seres Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Seres Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.6M | 1.9M | 1.8M | 2.4M | 15.1M | 15.9M | |
| Interest Expense | 502K | 2.9M | 2.9M | 6.0M | 13.2M | 13.8M | |
| Selling General Administrative | 24.7M | 30.8M | 69.3M | 79.7M | 87.7M | 92.1M | |
| Other Operating Expenses | 104.9M | 121.3M | 209.4M | 253.6M | 233.6M | 125.5M | |
| Operating Income | (71.9M) | (88.1M) | (64.5M) | (246.5M) | (107.3M) | (112.6M) | |
| Ebit | (71.9M) | (88.1M) | (64.5M) | (246.5M) | (107.3M) | (112.6M) | |
| Research Development | 80.1M | 90.6M | 141.9M | 172.9M | 145.9M | 87.5M | |
| Ebitda | (68.3M) | (86.2M) | (62.7M) | (244.1M) | (92.2M) | (96.8M) | |
| Total Operating Expenses | 104.9M | 121.3M | 209.4M | 253.6M | 218.5M | 124.1M | |
| Income Before Tax | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (119.4M) | |
| Total Other Income Expense Net | 1.6M | (997K) | (1.1M) | (3.7M) | (6.4M) | (6.1M) | |
| Net Income | (64.2M) | (86.5M) | (61.5M) | (253.8M) | (113.7M) | (119.4M) | |
| Income Tax Expense | (6.0M) | (2.7M) | (4.1M) | 3.7M | 3.3M | 3.5M | |
| Total Revenue | 34.5M | 33.2M | 144.9M | 7.1M | 126.3M | 132.6M | |
| Gross Profit | (45.6M) | (57.4M) | 143.2M | 6.1M | 111.2M | 116.8M | |
| Net Income From Continuing Ops | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (141.3M) | (148.3M) | |
| Cost Of Revenue | 80.1M | 90.6M | 1.7M | 1.0M | 15.1M | 14.4M | |
| Net Income Applicable To Common Shares | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (225.1M) | (213.9M) | |
| Interest Income | 1.0M | 946K | 2.9M | 3.1M | 6.7M | 7.1M | |
| Non Operating Income Net Other | 2.1M | 1.9M | 1.8M | 2.4M | 2.7M | 1.6M | |
| Net Interest Income | 531K | (2.0M) | (40K) | (3.0M) | (4.3M) | (4.1M) | |
| Reconciled Depreciation | 7.6M | 6.6M | 5.9M | 6.6M | 6.2M | 5.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 0.987 | Quarterly Revenue Growth (0.93) | Return On Assets (0.19) | Return On Equity (5.39) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.